We are investigating how effective Daratumumab is for patients with Monoclonal Gammopathy of Renal Significance in Finland. This study aims to understand its potential benefits for kidney health.
Health conditions and diseases that the clinical trial is designed to study and treat.
Monoclonal Gammopathy of Renal Significance (MGRS) is a condition where abnormal proteins produced by plasma cells can lead to kidney damage and dysfunction. It is often associated with symptoms related to kidney impairment.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.